<DOC>
	<DOCNO>NCT01725282</DOCNO>
	<brief_summary>In study , quetiapine XR placebo administer orally 6 week major depressive disorder patient lack response exist antidepressant , aim evaluate efficacy quetiapine XR dose-response three quetiapine XR dose group base change Montgomery-Asberg Depression Rating Scale ( MADRS ) score .</brief_summary>
	<brief_title>Study Evaluate Effect Safety Quetiapine Extended Release ( XR ) ( FK949E ) Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Diagnosis major depressive disorder specify Diagnostic Statistical Manual Mental Disorders , 4th edition , Text Revision ( DSMIVTR ) use MiniInternational Neuropsychiatric Interview ( M.I.N.I . ) Documented appropriate treatment history ( i.e. , lack response treatment label dosage least 4 week ) current major depression episode antidepressant use concomitantly study drug The Hamilton Depression Rating Scale ( HAMD17 ) total score 20 point HAMD17 depress mood score 2 point Concurrent previous history DSMIVTR Axis I disorder , except major depressive disorder , within last 6 month inform consent Concurrence DSMIVTR Axis II disorder consider greatly affect patient 's current mental status The duration current major depression episode short 4 week longer 24 month inform consent History dependence substance caffeine nicotine history abuse dependence alcohol The HAMD17 suicide score 3 point , history suicide attempt within last 6 month inform consent , risk suicide investigator 's subinvestigator 's opinion Concurrent previous history diabetes mellitus . HbA1c level 6.1 % ( Japan Diabetes Society value ) within past 2 month Electroconvulsive therapy within last 62 day primary registration ( within last 90 day secondary registration ) Treatment depot antipsychotic within last 28 day Documented suspected ( carrier ) condition renal failure , hepatic failure , serious cardiac disease ( current use antiarrhythmic drug ) , hepatitis B , hepatitis C , acquire immunodeficiency syndrome ( AIDS ) Concurrence uncontrolled hypertension ( define systolic blood pressure 180 mmHg , diastolic blood pressure 110 mmHg primary registration ) unstable angina may worsen study may affect study result base clinical judgment investigator subinvestigator Concurrence hypotension ( define systolic blood pressure le 100 mmHg primary registration ) orthostatic hypotension Concurrence malabsorption syndrome , hepatic disease , condition may affect absorption and/or metabolism study drug Concurrent previous history cerebrovascular disease transient ischemic attack ( TIA ) Known hypersensitivity quetiapine component FK949E tablet</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>patient</keyword>
	<keyword>FK949E</keyword>
</DOC>